ProSciento and LMC Diabetes Launch Strategic Partnership to Conduct Cross-Border Multi-Site Trials in Diabetes and Metabolism

Collaboration Brings Together Leading U.S. Metabolism-Focused CRO and Largest Canadian Diabetes Site Network

SAN DIEGO AND TORONTO, June 10, 2016 /PRNewswire/ –  ProSciento Inc., a science-driven clinical research organization (CRO) focused exclusively on metabolic diseases, and LMC Diabetes & Endocrinology, North America’s largest network of investigator sites for diabetes clinical research, announced today a strategic alliance focused on the conduct of cross-border, multi-site clinical research of investigational drugs and devices for diabetes and related metabolic disorders.

Under the terms of the agreement, ProSciento will expand its investigator network to include LMC’s 13 metabolism-focused clinical research sites in Canada. ProSciento will also provide clinical development planning as well as oversight of regulatory submissions to the U.S. FDA and Health Canada.

ProSciento is the only full scope CRO in the U.S. that is exclusively focused on metabolic diseases.  The company’s experience encompasses every clinically relevant drug class in diabetes, including early phase studies for many of the diabetes medications and devices on the market today. Headquartered in San Diego, ProSciento operates a dedicated clinical research facility that has completed over 240 phase I-IIa studies, as well as a network of more than 50 partnering sites for multi-center trials, which will now be expanded to include LMC’s 13 metabolism-focused sites in Canada.

LMC is the largest private diabetes clinical research network in North America. The company has conducted over 600 clinical trials across its 13 centers in Canada.  LMC sites adhere to 21 C.F.R. (Parts 50, 56), 45 C.F.R. (Part 46) and GCP standards to ensure clinical data is accepted by international regulatory agencies, including the FDA in the U.S. and the EMA in Europe.

“LMC has a long-standing track record of quality, success and expertise in conducting phase II/III metabolism-focused clinical trials, and we are delighted to welcome them as a strategic partner,” said Dr. Marcus Hompesch, ProSciento Chairman and CEO. “It is clear that cross-border development programs offer significant opportunities for cost and timeline efficiencies, as well as expanded patient-access.  This partnership represents an alliance between two metabolism centers of excellence building new and strengthening existing processes for cross-border clinical research and regulatory project management.”

“ProSciento’s focus on CRO services for metabolic diseases, most notably its unparalleled expertise in diabetes, and its track-record of rigorous adherence to quality and ethical standards in the U.S. fully aligns with LMC’s proven capabilities in multi-site clinical research conduct in Canada,” said Karri Venn, President of LMC’s Research Division.  “Together, we will be able to offer a compelling solution for the many sponsors who are seeking high quality CRO services coupled with deep metabolism expertise, as well as the efficiencies provided by conducting U.S./Canada cross-border clinical research.”

Cross-border drug and device development programs, with the right project management and monitoring oversight, can provide opportunities for cost and timeline efficiencies, as well as expanded patient-access.  Health Canada, the equivalent of the U.S. FDA, has a regulatory process that fosters the launch of clinical trials within 30 days.  Other incentives include competitive labor and facility costs, a favorable exchange rate for U.S. companies, and government tax credits of 15% to 32% for Canadian corporations.

About LMC Diabetes & Endocrinology

LMC is an industry leader, providing Phase I-IV clinical trial services in 13 sites with 35 endocrinologists, across four Canadian provinces. LMC Research is part of the LMC group of multi-disciplinary regional Centers of Excellence aimed at providing complete care in Diabetes, Endocrinology and Metabolism.   Specific areas of interest in research primarily focuses in diabetes and all complications, cardiovascular & metabolic disease, osteoporosis and women’s hormone health.

LMC investigators have been repeatedly recognized as the top enrolling sites globally and have contributed as many as 560 subjects to a single diabetes study. To date, LMC has conducted over 600 clinical trials across its centers and is a recognized by Sanofi as one of their Diabetes Centers of Excellence.  More information can be found at

About ProSciento, Inc.

ProSciento is a metabolism-focused, full scope clinical R&D services provider, with a mission to advance the global development of novel therapeutics for diabetes, NASH and obesity. The company is widely recognized for quality and scientific excellence, an unparalleled methodological toolkit, and extensive experience with virtually all metabolic drug and device classes. Utilizing its scalable R&D services model – combining deep therapeutic area expertise, strategic planning, an unparalleled methodological tool kit, and operational execution from late preclinical to phase III readiness – ProSciento provides highly customizable services for its global client base in today’s rapidly evolving landscape of metabolic drug and device development. For more information, please visit

For media inquiries, please contact:
Abby Devine
Senior Director, Corporate Communications, ProSciento, Inc.
Tel: +1 858 663-6148

For business development inquires:

For clinical study enrollment inquires:
Tel: +1 (866) 308-7427

Dennis R. DeRosia
LMC Diabetes & Endocrinology
+1 (949) 933-6485

(1) U.S. clinical trial data in diabetes, showing that ProSciento’s early phase facility in Chula Vista has completed more Ph I/II T1DM and T2DM studies in the U.S. than any other clinical research site, provided by Citeline’s SiteTrove, a service offered by Informa Pharma Intelligence, April 2016